We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. 

Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. 

By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

Health Data

Life Sciences

Medical Devices

Therapeutics

Precede Biosciences

Rehan Verjee

Matthew Eaton

Juliann Chmielecki

Corrie Painter

Kush Parmar

Jennifer Fortune

Geoff Otto

The Vice Presidents at Precede Biosciences spearhead critical strategic initiatives: The Vice President of External Research and Partnerships fosters collaborations with pharmaceutical companies and research institutions; the Vice President of Translational Sciences ensures the seamless application of research findings into clinical settings; and the Vice President of Computational Biology leads the development and integration of advanced computational techniques for analyzing biological data. Together, they drive the company's mission to advance precision medicine and diagnostic accuracy.

Vice Presidents

Leadership Team

Product Development Team

Associate Directors

Vice Presidents

About

Team members

Other teams at Precede Biosciences

Leadership Team

Product Development Team

Associate Directors